In this one-hour webinar, experts from Scientist.com and RockStep Solutions will discuss the digitalization of sample collection for dynamic in vivo studies. They will cover common challenges for researchers, technicians, and study monitors tasked with maintaining high-quality non-GLP study conduct in a fast-paced environment. Afterwards, they will present digital solutions and their application in real-world situations. A question and answer session will follow.

Discovery Life Sciences has developed a new bundled solution leveraging Illumina’s TruSight Oncology 500 (TSO00) Solid Tumor (FFPE) and cfDNA that delivers actionable, reliable NGS data across matched FFPE tumor and plasma biospecimens. These biomarkers can have relevance for disease detection, disease progression and relapse over time, and can indicate potential response to treatment for use in the discovery, development and validation of liquid biopsy tests and targeted oncology therapies.

To support the drug discovery community with the challenge to identify efficacious COVID-19 drugs, we have developed specific assays to block SARS-CoV-2 virus entry and replication. In this presentation we looked at biochemical protease assays we have in our COVID panel, including host proteases which enable viral entry (TMPRSS2, Furin, and Cathepsin L), as well as viral proteins involved in viral polyprotein processing (PLpro and Mpro). Next, we discussed our SPR assays for targeting viral entry by testing molecules that can block the interaction between the viral Spike protein (specially looking at the receptor binding domain in this work) and the host protein ACE2.

To address the challenges biobanks face during human biological sample provision, Scientist.com partnered with the UKCRC Tissue Directory and Coordination Centre (TDCC) to host a 3-part webinar series. Although the focus was on UK-based biobanks, the discussions and outcomes are globally applicable to any provider of human biological samples or research organization looking to procure human samples for scientific research. Find a debrief with summaries and videos of all three events below.

In mid-August, the Bio-Techne team shared their vast industry expertise in a webinar focusing on recombinant protein selection, customization and application. The featured panelists—Bio-Techne’s Martin Ramsden, Director Commercial Development and John Humphrey, Director Molecular and Cellular Biology—presented on recombinant protein applications, specifically biotinylated proteins, including site-specific Avi-tag biotinylation. Humphrey also spoke at length about COVID-19 SARS proteins available through Bio-Techne.

Wish you could get HEOR & RWE projects started faster, cheaper, & using the most optimal vendor? Do you want to connect with new buyers in this age of reduced face-to-face business development?

This on-demand webinar features speakers on-camera for greater interactivity & include a demonstration of the newly enhanced HEOR & RWE Marketplace, the pharma industry’s largest online marketplace for outsourced research. The webinar is presented by Marketplace partners HealthEconomics.Com & Scientist.com.

Meaghan Loy, MS, ALAT, SOT Associate Member and Category Director of In Vivo Services at Scientist.com hosted the  3-part webinar series that focused on animal welfare within scientific research. We collaborated with the UK’s National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) to co-host the series and had guests from  Mimetas, Hera Biolabs, and Sinclair Research to offer their technologies and solutions. Each webinar in the three-part educational series focused on the 3Rs of Animals in Research—Replacement, Reduction and Refinement—which are key factors in improving animal welfare in all types of research. Replacing animals with in vitro or in silico methods, reducing the numbers of animals used and refining procedures to reduce pain and distress are all critical to overall welfare. The 3Rs help us fulfill our moral and ethical obligations to the animals that have allowed many of the most important modern medical advances to occur. As straightforward as the 3Rs may sound, they can present a unique set of challenges upon implementation. It’s easy to continue conducting the same tried and true studies, but there are many recent innovations that researchers may not be aware of.

While female executives have outscored their male counterparts in many critical leadership competencies, they have also been perceived to lack strategic perspective and to be less “visionary” than men.  Learn what it means to be visionary in the life sciences industry, enhance your strategic thinking skills, and participate in lively discussions on how women can leverage their unique skills and competencies to demonstrate vision and strategic thinking.

For more than 20 years, the BIO CEO & Investor Conference has fueled biotech industry networking with premier investor and banking communities, focused on established and emerging publicly traded and select private biotech companies.

The virtual 2021 event, taking place February 16-18, will showcase the Biotechnology Innovation Organization’s (BIO) perspective on the new U.S. Congressional agenda, the record setting pacing of biotech IPOs and the hottest clinical developments and industry catalysts.

Build on the momentum from JPM Week and experience the best of biotech with three-days of productive BIO One-on-One Partnering meetings with institutional investors, industry analysts, and senior business development executives seeking potential investments and deal partners.